Scholarlink

Purpose of Review <p>Recurrent primary central nervous system lymphoma (PCNSL) has remained a challenging disease to treat with high rates of relapse with relatively short remissions. The purpose of this review was to assess the current landscape of treatment for recurrent PCNSL.</p> Recent Findings <p>Clinical trials have investigated treatments including methotrexate regimens, Bruton’s tyrosine kinase inhibitors, immunomodulatory drugs, immune checkpoint inhibitors, CAR-T, IRAK4 inhibitors, bispecific antibodies, and other targeted agents. Despite significant overall response rates (ORR), most studies yielded short nondurable remissions. More recent trials have therefore pursued combination of these novel agents. Preliminary data from selected active trials for recurrent PCNSL have indicated notable ORRs ranging from 50 to 94% and tolerable safety profiles.</p> Summary <p>Novel treatments have shown promise in treatment for recurrent PCNSL, significantly increasing available options at recurrence. Due to nondurable monotherapy responses, combination therapy of investigational agents has emerged as a consensus path forward for future clinical trials.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

An Update on Treatments for Recurrent Primary Central Nervous System Lymphoma

  • 期刊论文

  • 发表日期：

    2026年2月27日

查看全文
  • Joshua S. Friedman

摘要

Purpose of Review

Recurrent primary central nervous system lymphoma (PCNSL) has remained a challenging disease to treat with high rates of relapse with relatively short remissions. The purpose of this review was to assess the current landscape of treatment for recurrent PCNSL.

Recent Findings

Clinical trials have investigated treatments including methotrexate regimens, Bruton’s tyrosine kinase inhibitors, immunomodulatory drugs, immune checkpoint inhibitors, CAR-T, IRAK4 inhibitors, bispecific antibodies, and other targeted agents. Despite significant overall response rates (ORR), most studies yielded short nondurable remissions. More recent trials have therefore pursued combination of these novel agents. Preliminary data from selected active trials for recurrent PCNSL have indicated notable ORRs ranging from 50 to 94% and tolerable safety profiles.

Summary

Novel treatments have shown promise in treatment for recurrent PCNSL, significantly increasing available options at recurrence. Due to nondurable monotherapy responses, combination therapy of investigational agents has emerged as a consensus path forward for future clinical trials.